Patients with chronic hepatitis B virus infection died an average of 14 years younger and had higher incidences of death from all causes compared with the general U.S. population, according to study results recently published in Clinical Infectious Diseases.
“In the United States, about 1,800 death certificates annually list hepatitis B virus (HBV) as an underlying or contributing cause of death,” researchers wrote. “However, accurately quantifying mortal
For patients with chronic hepatitis B virus infection (CHB), serum mac-2-binding protein glycosylation isomer (M2BPGi) is a reliable marker for assessing liver fibrosis, according to results published in Clinical and Translational Gastroenterology.
M2BPGi presents a noninvasive alternative to the standard invasive liver biopsy for assessing liver fibrosis in CHB. Furthermore, M2BPGi appears to correlate well with histologic stages of liver fibrosis.
Af
Friday, June 22, 2018
News Recap:
Canada:
All Kids Should Have a Hepatitis B Shot. Clinicians and researchers attending an international conference say all Canadian children should be vaccinated against hepatitis B starting at birth to prevent the development of potentially deadly liver disease later in life, a policy recommended by the World Health Organization. Currently, most provinces and territories immunize children against the liver-destroyin...
TORONTO — Clinicians and researchers attending an international conference say all Canadian children should be vaccinated against hepatitis B starting at birth to prevent the development of potentially deadly liver disease later in life, a policy recommended by the World Health Organization.
Currently, most provinces and territories immunize children against the liver−destroying virus when they are much older, including Ontario and Nova Scotia, which sugg
Switching to tenofovir disoproxil fumarate (TDF) is more efficacious than continuing entecavir (ETV) for achieving an optimal response in patients with chronic hepatitis B with a partial virologic response to ETV, according to a multicenter, open-label, randomized controlled study published in the Journal of Viral Hepatitis.
No studies have directly compared the efficacy of switching from ETV to TDF with that of continuing ETV; therefore, researchers pros
This section is under development
In the meantime, here are some resources that you can consult.
HBV Pamphlet
http://hcvadvocate.org/hepatitis/factsheetsB_pdf/
A_Basic_Guide_to_Hepatitis_B.pdf
Friday, June 8, 2018
News Recap:
Canada:
New guidelines recommend hepatitis C screening be done for those born between 1945 and 1975. The Canadian Association for the Study of the Liver (CASL), a national group of health-care providers and researchers, published its guidelines on testing and treating hepatitis C in Monday's edition of the CMAJ. Canadians born between 1945 and 1975 – essentially the baby-boom generation – should be tested for the pot...
Researchers at the University of Delaware, working with colleagues at Indiana University, have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
The discovery, which was published April 27 in the journal eLife, reveals previously unknown details about the capsid, or protein shell, that encloses the virus' genetic blueprint.
Scientists believe th
Friday, June 1, 2018
News Recap:
HCV:
Large Study Confirms DAAs Protect Against HCC When Sustained Viral Response Achieved. Patients with hepatitis C virus who are successfully treated with direct-acting antiviral agents experience a dramatic reduction in their risk for liver cancer, new data show. However, the decrease is much lower for those diagnosed with cirrhosis before starting a DAA.
HCV Guidance Updated for Screening and Treating Key Popu...
About 85% of a cohort of Alaskans who received the hepatitis B vaccine at age 6 months or older showed evidence of protection after 35 years, although some may require a booster dose, according to a study presented at the 2017 Liver Meeting.
“No chronic hepatitis B infections were identified in the cohort,” according to lead study author Michael Bruce, MD, MPH, an epidemiology team leader in the CDC’s Arctic Investigation Program Division of Preparedness
